Composition
1 TABLET WEIGHT 1720 mg CONTAINS:
- L-Carnitine tartrate 500 mg
- Coenzyme Q 10 40 mg
- Quercetin dehydrate 25 mg
COMPOSITION: L-carnitine tartrate, coenzyme Q 10, quercetin dehydrate, maltodextrin, microcrystalline cellulose, croscarmellose sodium, gastro-resistant coating (ethylcellulose, medium chain triglycerides, oleic acid, ammonium hydrochloride, sodium alginate, stearic acid Europharm), silicon dioxide, stearic acid Europharm of vegetable origin, magnesium stearate Europharm of vegetable origin, hydroxypropylmethylcellulose, glycerin Europharm of vegetable origin.
Nutritional (food) and energy value (calories)
Nutritional (food) and energy value (calories) per 100 (g): proteins - 43.7 g, carbohydrates - 17.7 g, fats - 2.5 g; 1151.02 kJ/ 274.97 kcal.
Per 1 tablet: proteins - 0.74 g, carbohydrates - 0.3 g, fats - 0.04 g; 19.58 kJ / 4.68 kcal.
Recommendations for use
It can be recommended by a doctor for use in dietary diets as a source of vitamins, biologically active substances for the purpose of general strengthening of the body and creation of optimal dietary conditions for metabolism, in particular acceleration of fat metabolism, stimulation of cell and tissue regeneration, increase of appetite. The product increases tolerance to stress and increases adaptive capabilities of the human body. It has a powerful anti-inflammatory and anti-allergic effect, strengthens and restores connective tissue, helps to lower cholesterol levels, enhances the effect of many beneficial substances. Increases the resistance of body tissues to the harmful effects of excessive sugar content in the blood, reduces the likelihood of diabetes, and also facilitates the course of existing forms. It has a positive effect on the nervous system, activates nervous processes. It helps to slow down the aging process of the body, prolong mental and physical activity, and improve the quality of life.
Recommended for ischemic and hypoxic conditions of the myocardium and brain, to improve blood circulation, metabolism and restore functional activity, during intense physical exertion, to improve muscle activity, to increase resistance to stress, to reduce weight by breaking down fats, for diabetic diseases, to improve metabolic processes, in children and adolescents with growth retardation and insufficient muscle mass. In renal failure to eliminate primary and secondary carnitine deficiency. For rehabilitation after serious illnesses and operations.
Contraindication
Individual intolerance to the product or individual components.
Reservation
Xinocard is usually well tolerated. Rarely: allergic reactions, weakness. Overdose symptoms: dizziness, spastic abdominal pain, nausea, vomiting. Overdose treatment: gastric lavage is possible, if necessary, symptomatic therapy. During pregnancy, breastfeeding and children, the product should be taken only on the recommendation of a doctor.
Method of application
When used by the consumer on their own, it is recommended to take 1 tablet once a day. If the product is prescribed by a doctor, the dosage may be changed: 1 tablet 2-3 times a day after meals, washed down with sufficient water. The course of treatment is 1-2 months. Do not exceed the recommended daily dose. Do not use the drug as a substitute for a full and balanced diet.
CONSULTATION WITH A DOCTOR IS RECOMMENDED BEFORE USE.
Release form
No. 30. 10 tablets in a blister, 3 blisters together with an insert sheet in a cardboard box.
Storage conditions
Store in the manufacturer's packaging at a temperature not exceeding 25°C, in a dry, dark place, out of reach of children. Do not freeze.
Expiration date
3 years from the date of manufacture. Do not use the drug after the expiration date.
NOT A MEDICINE. DOES NOT CONTAIN GMOs. THIS MEDICINE IS SUITABLE FOR VEGETARIANS.
Producer
PRODUCT OF THE COMPANY “NOVATOR PHARMA”, Great Britain.
THE OWNER OF THE TRADEMARK IS THE COMPANY “NOVATOR PHARMA” Great Britain. NAME AND LOCATION OF THE IMPORTER (FOR COMMUNICATION WITH THE CONSUMER): LLC “NOVATOR PHARMA”, 04071, Ukraine, Kyiv, Yaroslavska St., 4-B, office 5.
MANUFACTURER: PRIMEA LIMITED, 20-22 Wenlock Road, London, England, No. 1.
RESEARCH PROTOCOL ON SAFETY INDICATORS: No. 9132 / 1714-5 dated November 21, 2018, SE "Scientific Center for Preventive Toxicology, Food and Chemical Safety named after Acad. L. I. Medved, Ministry of Health of Ukraine".
